Overdose of low molecular weight heparin in an infant with stage 5 chronic kidney disease treated with hemofiltration.

Beejal Patel, Matko Marlais, Mary Mathias, Samikska Shetty, Liam Watson, Deirdre O' Sullivan

Abstract readCase Reports

In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Beejal PatelDepartment of Paediatric Nephrology, Great Ormond Street Hospital for Children, London, UK.

Matko MarlaisDepartment of Paediatric Nephrology, Great Ormond Street Hospital for Children, London, UK.

Mary MathiasDepartment of Clinical Haematology, Great Ormond Street Hospital for Children, London, UK.

Samikska ShettyDepartment of Paediatric Nephrology, Great Ormond Street Hospital for Children, London, UK.

Liam WatsonDepartment of Paediatric Intensive Care, Great Ormond Street Hospital for Children, London, UK.

Deirdre O' SullivanDepartment of Paediatric Nephrology, Great Ormond Street Hospital for Children, London, UK. Deirdre.osullivan@gosh.nhs.uk.ORCID http://orcid.org/0000-0002-2269-8177

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low molecular weight heparin (LMWH) is widely used for the treatment and prevention of many venous thromboembolic disorders. LMWH acts through its ability to potentiate inhibition of factor Xa. LMWH undergoes primary renal excretion and therefore its elimination can be severely impacted by kidney disease. We report on the case of an infant with stage 5 chronic kidney disease (CKD) who received a prolonged accidental overdose of dalteparin. The infant was symptomatic with a falling haemoglobin, perinephric hematoma, and oozing venipuncture sites. Given the inability to predict drug clearance in this infant and her significant risk of bleeding, she underwent a successful trial of continuous veno-venous hemofiltration (CVVH) for the treatment of LMWH overdose. Whilst on CVVH, a steady downward trend in anti-Xa levels over 24 h was observed.

Indexed as

AnticoagulantsDalteparinDrug OverdoseHemofiltrationHeparin, Low-Molecular-WeightRenal Insufficiency, ChronicHumansInfantTreatment OutcomeAnticoagulantsDalteparinHeparin, Low-Molecular-WeightChronic kidney diseaseHemofiltrationLow molecular weight heparinOverdose

Identifiers

PMID40728746

DOI10.1007/s00467-025-06919-7

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.